digoxin and Hepatic-Encephalopathy

digoxin has been researched along with Hepatic-Encephalopathy* in 2 studies

Other Studies

2 other study(ies) available for digoxin and Hepatic-Encephalopathy

ArticleYear
Vasodilatory state of decompensated cirrhosis: relation to hepatic dysfunction, ascites, and vasoactive substances.
    Alcoholism, clinical and experimental research, 1995, Volume: 19, Issue:1

    The objective of this study was to determine the relations between the hallmark circulatory finding of decompensated cirrhosis, a reduced systemic vascular resistance (SVR), and the indices of hepatic decompensation, the accumulation of ascites, and the concentrations of various vasoactive substances. At a university-affiliated teaching hospital, eighteen hospitalized patients with cirrhosis and 18 age- and sex-matched healthy subjects were used. This was a case-control study. Measurements included cardiac dimensions and indices derived from echocardiograms and Doppler studies, abdominal ultrasound estimates of ascites, indices of hepatic function, and various serum (S) and urinary (U) substances. Results showed that cirrhotics had increased left atrial and left ventricular dimensions, left ventricular mass, heart rate, cardiac output (CO), transvalvular velocities, and a decreased SVR. SVR was related to hepatic dysfunction, as reflected by an abnormal prothrombin time ratio (r = -0.64, p = 0.006), and also related to overall severity of liver disease as estimated by the Child-Pugh score (r = -0.53, p = 0.044). Although cirrhotics with ascites generally had a reduced SVR, estimates of ascites were directly related to SVR (r = 0.57, p = 0.03) and inversely related to CO (r = -0.53, p = 0.04). Concentrations of S and U digoxin-like immunoreactive substance (DLIS) were also increased, but the concentrations of S glucagon and estradiol were not elevated. The accumulations of S and U DLIS, S glucagon, and S estradiol were all related to hepatic dysfunction.(ABSTRACT TRUNCATED AT 250 WORDS)

    Topics: Adult; Ascites; Blood Proteins; Cardenolides; Digoxin; Echocardiography; Echocardiography, Doppler; Estradiol; Female; Glucagon; Hemodynamics; Hepatic Encephalopathy; Humans; Liver Cirrhosis, Alcoholic; Liver Function Tests; Male; Middle Aged; Saponins; Vascular Resistance; Vasodilation; Ventricular Function, Left; Water-Electrolyte Balance

1995
[Endogenous digitalis-like factor in liver cirrhosis and cholestasis].
    Zeitschrift fur Gastroenterologie, 1993, Volume: 31 Suppl 2

    Endogenous digitalis-like factor (EDLF), an inhibitor of membrane Na+/K(+)-ATPase, is discussed to be involved in the pathogenesis of cirrhogenic portal hypertension, ascites formation and development of functional hepatorenal failure. Therefore, we investigated the serum content of this mediator in patients with liver cirrhosis Child-Pugh stage A, B, and C (n = 27) by means of enzyme immunoassay with a specific digoxin antibody. Furthermore, a correlation analysis was performed in order to find out correlations between signs of cell injury, cholestasis, synthetic cell function, ascites formation, and hepatorenal failure. Our results demonstrate that EDLF is significantly elevated in Child C cirrhosis (0.61 +/- 0.15 ng/ml) in comparison to Child A cirrhosis (0.013 +/- 0.2 ng/ml) and is also higher than in Child B cirrhosis (0.23 +/- 0.25 ng/ml). In patients without ascites EDLF (0.056 +/- 0.19 ng/ml) differs significantly from that of patients with non-complicated ascites (0.156 +/- 0.176 ng/ml) and from that of patients with therapy refractory ascites (0.66 +/- 0.17 ng/ml) or hepatorenal failure (1.56 ng/ml). There are no correlations between EDLF and renal function. Significant correlations were demonstrated for cholestasis (serum bilirubin), synthesis function (serum protein, Quick's value, cholinesterase, fibrinogen, albumin), and the degree of portasystemic encephalopathy (number connection test). We conclude that EDLF may act as a mediator in the process of progressive portal hypertension and its complications due to cirrhosis. This process of progression is caused by the inhibition of Na+/K(+)-ATPase, vasoconstriction, and endothelin secretion.

    Topics: Adult; Ascites; Bilirubin; Blood Proteins; Cardenolides; Digoxin; Enzyme Inhibitors; Female; Hepatic Encephalopathy; Hepatorenal Syndrome; Humans; Hypertension, Portal; Immunoenzyme Techniques; Kidney Function Tests; Liver; Liver Cirrhosis; Liver Function Tests; Male; Prothrombin Time; Saponins; Serum Albumin; Sodium-Potassium-Exchanging ATPase

1993